Literature DB >> 1615136

Rate of increase of plasma drug level influences subjective response in humans.

H de Wit1, B Bodker, J Ambre.   

Abstract

This study addressed the commonly held, but seldom tested, notion that faster rates of increase of drug effects are associated with more positive subjective effects. Sodium pentobarbital was administered to normal healthy volunteers in either a single oral dose or in a series of divided, cumulating doses, and subjective responses were monitored. Twelve subjects participated in three weekly sessions, during which they received capsules containing placebo, 150 mg pentobarbital in a single dose (SIN) or 180 mg pentobarbital administered in six divided doses (DIV) of 30 mg every 30 min. Doses of pentobarbital in the SIN and DIV were selected to produce similar peak plasma levels. Blood samples were obtained at regular intervals for plasma drug level determinations, and throughout the session subjects completed self-report mood questionnaires (e.g., Profile of Mood States, visual analog ratings of drug liking and drug "high") and psychomotor performance tests (e.g., Digit Symbol Substitution Test). As expected, the SIN and DIV conditions yielded similar peak levels of pentobarbital, but the peak was attained more rapidly in the SIN condition. Despite the similarity in peak plasma levels, subjects reached greater peaks in ratings of "high" and wanted more of the drug when they were in the SIN condition. On an end-of-session liking questionnaire they also reported significantly greater liking of the drug in the SIN condition. On other measures of drug effects (e.g., sedation and psychomotor impairment) no significant differences were observed between the conditions. Thus, the rate of increase of the drug's effects specifically influenced subjects' ratings on subjective measures (e.g., "high" and liking) that may be associated with risk for abuse.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615136     DOI: 10.1007/bf02245161

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  The durations of action of thiopental and pentobarbital.

Authors:  A GOLDSTEIN; L ARONOW
Journal:  J Pharmacol Exp Ther       Date:  1960-01       Impact factor: 4.030

Review 2.  Benzodiazepines and human memory: a review.

Authors:  M M Ghoneim; S P Mewaldt
Journal:  Anesthesiology       Date:  1990-05       Impact factor: 7.892

3.  Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers.

Authors:  H deWit; J Pierri; C E Johanson
Journal:  Pharmacol Biochem Behav       Date:  1989-05       Impact factor: 3.533

4.  Six weeks of diazepam treatment in normal women: effects on psychomotor performance and psychophysiology.

Authors:  D R McLeod; R Hoehn-Saric; A S Labib; D J Greenblatt
Journal:  J Clin Psychopharmacol       Date:  1988-04       Impact factor: 3.153

5.  Narcotic blockade.

Authors:  V P Dole; M E Nyswander; M J Kreek
Journal:  Arch Intern Med       Date:  1966-10

6.  Profile of acute tolerance to three sedative anxiolytics.

Authors:  E H Ellinwood; M Linnoila; M E Easler; D W Molter
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs.

Authors:  O B Paulson; A Györy; M M Hertz
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

8.  Benzodiazepines: a summary of pharmacokinetic properties.

Authors:  D J Greenblatt; R I Shader; M Divoll; J S Harmatz
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

9.  Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; J S Harmatz; K Franke; J Koch-Weser
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

10.  Drug preference and mood in humans: diazepam.

Authors:  C E Johanson; E H Uhlenhuth
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  44 in total

1.  The rate of intravenous cocaine administration determines susceptibility to sensitization.

Authors:  Anne-Noel Samaha; Yilin Li; Terry E Robinson
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

2.  Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.

Authors:  Mona Darwish; Mary Bond; William Tracewell; Philmore Robertson; Ronghua Yang
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

3.  Thinking outside the synapse: pharmacokinetic-based medications for cocaine addiction.

Authors:  Paul W Czoty; David C S Roberts
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

4.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

5.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

Review 6.  Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.

Authors:  N G Schneider; E Lunell; R E Olmstead; K O Fagerström
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

7.  Subjective and behavioral effects of diazepam depend on its rate of onset.

Authors:  H de Wit; S Dudish; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Familial aggregation of tobacco use behaviors among Amish men.

Authors:  Katie L Nugent; Amber Million-Mrkva; Joshua Backman; Sarah H Stephens; Robert M Reed; Peter Kochunov; Toni I Pollin; Alan R Shuldiner; Braxton D Mitchell; L Elliot Hong
Journal:  Nicotine Tob Res       Date:  2014-02-28       Impact factor: 4.244

Review 9.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Can abuse deterrent formulations make a difference? Expectation and speculation.

Authors:  Simon H Budman; Jill M Grimes Serrano; Stephen F Butler
Journal:  Harm Reduct J       Date:  2009-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.